Literature DB >> 32690655

Human Hepatitis B Viral Infection Outcomes Are Linked to Naturally Occurring Variants of HLA-DOA That Have Altered Function.

Austin M Graves1,2, Francesca Virdis1, Eliot Morrison3, Miguel Álvaro-Benito3, Aly A Khan4, Christian Freund3, Tatyana V Golovkina5, Lisa K Denzin6,7,8.   

Abstract

HLA molecules of the MHC class II (MHCII) bind and present pathogen-derived peptides for CD4 T cell activation. Peptide loading of MHCII in the endosomes of cells is controlled by the interplay of the nonclassical MHCII molecules, HLA-DM (DM) and HLA-DO (DO). DM catalyzes peptide loading, whereas DO, an MHCII substrate mimic, prevents DM from interacting with MHCII, resulting in an altered MHCII-peptide repertoire and increased MHCII-CLIP. Although the two genes encoding DO (DOA and DOB) are considered nonpolymorphic, there are rare natural variants. Our previous work identified DOB variants that altered DO function. In this study, we show that natural variation in the DOA gene also impacts DO function. Using the 1000 Genomes Project database, we show that ∼98% of individuals express the canonical DOA*0101 allele, and the remaining individuals mostly express DOA*0102, which we found was a gain-of-function allele. Analysis of 25 natural occurring DOα variants, which included the common alleles, identified three null variants and one variant with reduced and nine with increased ability to modulate DM activity. Unexpectedly, several of the variants produced reduced DO protein levels yet efficiently inhibited DM activity. Finally, analysis of associated single-nucleotide polymorphisms genetically linked the DOA*0102 common allele, a gain-of-function variant, with human hepatitis B viral persistence. In contrast, we found that the DOα F114L null allele was linked with viral clearance. Collectively, these studies show that natural variation occurring in the human DOA gene impacts DO function and can be linked to specific outcomes of viral infections.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32690655      PMCID: PMC7415708          DOI: 10.4049/jimmunol.2000476

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

1.  Mapping the HLA-DO/HLA-DM complex by FRET and mutagenesis.

Authors:  Taejin Yoon; Henriette Macmillan; Sarah E Mortimer; Wei Jiang; Cornelia H Rinderknecht; Lawrence J Stern; Elizabeth D Mellins
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-25       Impact factor: 11.205

2.  HLA-DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport.

Authors:  M Liljedahl; T Kuwana; W P Fung-Leung; M R Jackson; P A Peterson; L Karlsson
Journal:  EMBO J       Date:  1996-09-16       Impact factor: 11.598

3.  Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization.

Authors:  P A Roche; C L Teletski; E Stang; O Bakke; E O Long
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

Review 4.  Mechanisms of peptide repertoire selection by HLA-DM.

Authors:  Wouter Pos; Dhruv K Sethi; Kai W Wucherpfennig
Journal:  Trends Immunol       Date:  2013-07-05       Impact factor: 16.687

5.  Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection.

Authors:  S A Villano; D Vlahov; K E Nelson; S Cohn; D L Thomas
Journal:  Hepatology       Date:  1999-03       Impact factor: 17.425

6.  Identification of four novel HLA-DOA alleles, DOA*010106, DOA*0102, DOA*0103, and DOA*0104N, by sequence-based typing*.

Authors:  S-M Moon; H Gu; H-J Ryu; J-J Kim; H-T Kim; B-G Han; K Kimm; J-K Lee; B Oh
Journal:  Tissue Antigens       Date:  2005-09

Review 7.  Conformational variation in structures of classical and non-classical MHCII proteins and functional implications.

Authors:  Corrie A Painter; Lawrence J Stern
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

8.  Association of the rs3077 and rs9277535 polymorphisms in HLA-DP with hepatitis B virus infection and spontaneous clearance: a meta-analysis.

Authors:  Xiao-Lin Zhang; Xiao-Chen Ni; Jin-Hai Jia; Jing-Hui Dong; Feng-Xue Yu; Ning Ma; Xue-Hui Liu; Man Li; Dian-Wu Liu
Journal:  Scand J Gastroenterol       Date:  2013-04-22       Impact factor: 2.423

9.  Germinal center B cells regulate their capability to present antigen by modulation of HLA-DO.

Authors:  Kim S Glazier; Sandra B Hake; Helen M Tobin; Amy Chadburn; Elaine J Schattner; Lisa K Denzin
Journal:  J Exp Med       Date:  2002-04-15       Impact factor: 14.307

10.  HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism.

Authors:  Abigail I Guce; Sarah E Mortimer; Taejin Yoon; Corrie A Painter; Wei Jiang; Elizabeth D Mellins; Lawrence J Stern
Journal:  Nat Struct Mol Biol       Date:  2012-12-09       Impact factor: 15.369

View more
  4 in total

1.  Mouse Homologue of Human HLA-DO Does Not Preempt Autoimmunity but Controls Murine Gammaherpesvirus MHV68.

Authors:  Jean Lee; Emily Cullum; Kyle Stoltz; Niklas Bachmann; Zoe Strong; Danielle D Millick; Lisa K Denzin; Anthony Chang; Vera Tarakanova; Alexander V Chervonsky; Tatyana Golovkina
Journal:  J Immunol       Date:  2021-11-22       Impact factor: 5.426

2.  Genetic Control of Neonatal Immune Tolerance to an Exogenous Retrovirus.

Authors:  Emily Cullum; Stanislav Dikiy; Helen A Beilinson; Melissa Kane; Alessandra Veinbachs; Vera M Beilinson; Lisa K Denzin; Alexander Chervonsky; Tatyana Golovkina
Journal:  J Virol       Date:  2020-11-23       Impact factor: 5.103

3.  MHC Class II Presentation Is Affected by Polymorphism in the H2-Ob Gene and Additional Loci.

Authors:  Emily Cullum; Austin M Graves; Vera L Tarakanova; Lisa K Denzin; Tatyana Golovkina
Journal:  J Immunol       Date:  2021-06-16       Impact factor: 5.422

4.  Type 1 Diabetes and the HLA Region: Genetic Association Besides Classical HLA Class II Genes.

Authors:  Jana Sticht; Miguel Álvaro-Benito; Stefan Konigorski
Journal:  Front Genet       Date:  2021-06-17       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.